Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

A Study of a Vaccine in Combination with Beta-glucan in People with Neuroblastoma

Trial Status: active

This phase II trial tests the effectiveness of bivalent vaccine, saponin-based immunoadjuvant OBI-821 (OPT-821 [QS-21]), in combination with beta-glucan in treating patients with neuroblastoma that has a higher chance of coming back or resisting standard treatment (high-risk). A bivalent vaccine, such as OPT-821 (QS-21), works by stimulating an immune response against two different antigens, which are specific proteins on the surface of a cell. OPT-821 (QS-21) stimulates an immune response against GD2L and GD3L that are found on neuroblastoma cells and trains the immune system to make antibodies against them. Beta-glucan is a kind of sugar from yeast and may help white blood cells kill tumor cells. Giving OPT-21 (QS-21) vaccine in combination with beta-glucan may kill more tumor cells in patients with high-risk neuroblastoma.